Californian medical company Second Sight has been granted conditional approval by the US Food and Drug Administration to conduct small clinical trial of its new device, the Orion, which could restore some vision to patients with retinitis pigmentosa. The Orion is a tiny device that uses an array of electrodes implanted in the eye socket to stimulate nerve cells within the retina, restoring vision. The company, Second Sight, is testing whether an array of electrodes placed on the surface of the brain can return limited vision to people who have gone partially or completely blind. The company said people who are blind due to other illnesses could "hypothetically" use the Orion.
Californian medical company Second Sight has been granted conditional approval by the US Food and Drug Administration to conduct small clinical trial of its new device, the Orion, which could restore some vision to patients with retinitis pigmentosa. The Orion is a tiny device that uses an array of electrodes implanted in the eye socket to stimulate nerve cells within the retina, restoring vision. The company said people who are blind due to other illnesses could "hypothetically" use the Orion.